Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  5-Amino-1MQ (NNMT inhibitor)

Research reference — not for sale

5-Amino-1MQ (NNMT inhibitor)

F

lead outcome

Fat loss / anti-obesity

grades vary by outcome ↓

Small molecule (non-peptide)

also called — 5-Amino-1MQ · 5-amino-1-methylquinolinium (iodide) · 5A1MQ · an NNMT inhibitor (NNMTi). INCI: none

metabolicfat loss (adipose-direct)NAD⁺ / cellular energy(preclinical:) muscle-stem-cell / aging

The "cellular optimization" fat-loss molecule — mechanistically elegant, entirely animal-tested. Three points define this entry: (1) it is not a peptide — a small-molecule enzyme inhibitor, expanding the register's non-peptide tier; (2) it works by a genuinely different route from GLP-1 drugs — directly on fat cells (inhibiting the enzyme NNMT), not by suppressing appetite; (3) the preclinical story is compelling and well-cited — but there is zero completed human data, so the honest grade is capped low despite the elegant mechanism.

In brief

5-Amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) studied for fat loss through a mechanism quite different from GLP-1 drugs: instead of curbing appetite, it acts inside fat cells. NNMT normally consumes SAM (the cell's methyl donor) and pulls nicotinamide out of the NAD⁺ salvage pathway; inhibiting it raises SAM and NAD⁺, boosting sirtuin (SIRT1/3) activity, fat oxidation, thermogenesis and polyamine flux — and NNMT is expressed highest in adipose tissue, offering the theoretical appeal of a fat-targeted intervention. The preclinical evidence is genuinely interesting: in diet-induced obese mice, 5-Amino-1MQ reduced body weight, fat mass, adipocyte size (~30–40%) and total cholesterol (~30%) without changing food intake or lean mass, and a separate line showed muscle-stem-cell reactivation in aged mice. The decisive caveat: every efficacy result is in rodents or cell culture. There are no completed human trials, no published human pharmacokinetics, and no approval anywhere. Elegant mechanism, essentially no human proof.

Legal standing, by region

European Union

Not FDA-approved (gray-market)

not approved anywhere; investigational research chemical. Not a cosmetic; not on the FDA 503A bulk-compounding list (no legitimate compounding/clinical access route). Sold as a "research use only" small molecule.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Fat loss / anti-obesity

Compelling but rodent-only; "no change in food intake" is a genuinely interesting mechanistic point, but it's still animals. No human efficacy

Neelakantan 2018 (DIO mice, ~/day): ↓body weight, ↓fat mass, ↓adipocyte size, no change in food intake; target-validated by Kraus 2014 (genetic knockdown, Nature)

F

NNMT as an obesity target (validation)

The target is well-validated (including some human correlational data); the drug is not — don't conflate them

Kraus 2014 Nature (knockdown) + human adipose NNMT-expression correlations (Kannt 2015)

C

Muscle stem cells / aging / recomposition

Aged-mouse only; intriguing "recomp" angle but no human data

Neelakantan 2019 (aged mice: stem-cell reactivation, ~70% peak-torque gain)

F

Lipids / insulin sensitivity

Preclinical; specific LDL / clinical-lipid effects not established

Mouse: ~30% lower total cholesterol; Kraus/Brachs: improved insulin sensitivity (glucose tolerance less consistent)

F

Human efficacy or safety (any use)

The defining gap: bioavailability, half-life, dosing, safety in humans are all unknown

None — no completed human trials, no published PK

F

Safety (animal)

Reassuring in mice over days; says nothing about human safety or chronic use

Short rodent studies: "no observable toxicity" over ~11 days

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for 5-Amino-1MQ (NNMT inhibitor) changes - nothing else.

Identity

a small, orally-bioavailable molecule (a quinolinium salt, not a peptide) engineered as a selective, substrate-competitive inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme most highly expressed in adipose (fat) tissue. Its quinolinium ring mimics the nicotinamide substrate, letting it occupy NNMT's active site and block the methylation reaction. It appears in "peptide" catalogues because of the metabolic-medicine crowd it travels with, but chemically it belongs with the register's non-peptide tier (alongside MK-677, Orforglipron, Noopept).

Mechanism (as proposed)

NNMT (nicotinamide N-methyltransferase) sits at a metabolic crossroads. It methylates nicotinamide (using SAM, the universal methyl donor) to make 1-MNA — a reaction that both burns SAM and removes nicotinamide from the NAD⁺ salvage pathway. When NNMT is overactive (as it is in obese/aged adipose tissue), it depletes NAD⁺ and SAM. 5-Amino-1MQ blocks NNMT's active site, so both pools rise: more NAD⁺ fuels sirtuins (SIRT1/SIRT3) → more fat oxidation, mitochondrial activity and energy expenditure; more SAM feeds polyamine flux and histone methylation that shift adipocytes toward thermogenesis and away from fat storage. Because NNMT is concentrated in fat tissue, the effect is relatively tissue-targeted — the theoretical selling point. The framing is "cellular optimization" (fixing a metabolic inefficiency inside the cell) rather than the "hormonal manipulation" of incretin drugs.

Sources — 5 cited

01Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258-262 (target validation; genetic, not 5A1MQ).

02Neelakantan H, et al. Selective and membrane-permeable small-molecule NNMT inhibitors reverse high-fat-diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152 (the defining 5-Amino-1MQ paper).

03Neelakantan H, et al. Small-molecule NNMT inhibitor activates muscle stem cells and improves muscle regeneration in aged mice. Biochem Pharmacol. 2019 (muscle branch).

04Kannt A, et al. NNMT mRNA in human adipose tissue and plasma 1-MNA with insulin resistance. Diabetologia. 2015 (human correlational).

05Brachs S, et al. (2019) — genetic NNMT loss, insulin sensitivity. Note: no human interventional PK/efficacy data published as of 2026.

Updated 2026-07-13 (watch for first-in-human PK/efficacy trials — that would be the first thing to move any grade off F)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

SLU-PP-332 (ERR agonist / "exercise mimetic")F

Small molecule (non-peptide)

Humanin (HN / HNG / S14G-Humanin)C

AOD-9604 (hGH fragment 176-191 analog)F

Explore by goal

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.